大桐制药

Daitong Pharmaceutical is an innovative biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of targeted protein degradation (TPD) therapeutics. The company utilizes its proprietary D-Glue and D-PROTAC platforms to develop molecular glues and proteolysis-targeting chimeras for challenging targets in oncology and autoimmune diseases. Daitong's lead programs focus on degrading proteins that are traditionally considered undruggable, aiming to provide new treatment options for patients with resistant or refractory cancers. Led by a team of experienced scientists from global pharmaceutical companies, Daitong has successfully advanced its first molecular glue degrader into clinical trials. The company is backed by prominent life science investors and continues to expand its pipeline of novel degraders.